Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CDX 301

Drug Profile

CDX 301

Alternative Names: CDX-301; Flt-3 ligand; Flt3-L; Fms-like tyrosine kinase 3 ligand - Celldex Therapeutics; Mobista; rhuFlt3L

Latest Information Update: 14 Jun 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Amgen
  • Developer Albert Einstein College of Medicine; Amgen; Celldex Therapeutics Inc; Icahn School of Medicine at Mount Sinai; Merck Sharp & Dohme
  • Class Adjuvants; Antineoplastics; Antiretrovirals; Cytokines; Recombinant proteins
  • Mechanism of Action Fms-like tyrosine kinase 3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II B-cell lymphoma; Breast cancer; Head and neck cancer; Non-Hodgkin's lymphoma
  • Phase I Prostate cancer; Solid tumours
  • Preclinical HIV infections
  • Discontinued Autoimmune disorders; Infections; Malignant melanoma; Stem cell mobilisation

Most Recent Events

  • 29 May 2020 Efficacy and adverse events data from a phase II trial in Non-small cell lung cancer presented at the 56th Annual Meeting of the American Society of Clinical Oncology (ASCO-2020)
  • 08 Mar 2020 Pharmacodynamics data from the preclinical study in HIV-infections presented at the 27th Conference on Retroviruses and Opportunistic Infections (CROI-2020)
  • 01 Mar 2020 Preclinical trials in HIV infections in USA (unspecified route), before March 2020
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top